在严重和耐火性IgA脏病中添加贝利马布的有益作用:一个病例报告
Youying Mao1,2, Chenxing Zhang1, Jing Xu3
1Department of Nephrology, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Pediatric nephrology (Berlin, Germany)
|January 8, 2025
概括
在传统疗法失败的儿童中,贝利马布对治疗严重的IgA脏病 (IgAN) 是有前途的. 这种方法导致脏改善和血细胞减少,为耐火性Igan患者提供了新的希望.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 免疫学 免疫学 免疫学
- 儿科 儿科 儿科
背景情况:
- 在全球范围内,尤其是中国,IgA病 (IgAN) 是慢性病 (CKD) 的主要原因.
- 耐火性IGAN缺乏经过标准治疗的确定的治疗方法.
- 贝利马布是一种B淋巴细胞刺激抑制剂,已被批准用于狼性炎.
研究的目的:
- 报告贝利马布在患有严重,耐火性IgA脏病的儿科病例中的疗效.
- 评估贝利穆马布对功能和IgAN血细胞水平的影响.
主要方法:
- 一个儿童患有严重IgA脏病的案例研究.
- 在现有的免疫抑制疗法中添加贝利穆马布.
- 监测脏反应和外周血细胞计数.
主要成果:
- 在添加belimumab后观察到显著的脏反应.
- 与治疗相关的周围血液等离子体细胞的减少.
- 这代表了贝利穆马布在耐火性IgAN中使用的首个报告案例.
结论:
- 贝利马布与常规免疫抑制剂相结合,可能对儿童严重的耐火性IgA脏病有好处.
- 血细胞的减少表明了潜在的作用机制.
- 需要进一步的研究,以在更大的队列中证实这些发现.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Inflammatory Bowel Disease IV: Pharmacological Management
110
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
110
Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
Dipeptidyl Peptidase 4 Inhibitors
166
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
166
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95


